BBA
SGMO

Baker Bros. Advisors’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Baker Bros. Advisors’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-429,063
Closed -$5.38M – 126
2021
Q1 		$5.38M Sell
429,063
-428,276
-50% -$5.77M 0.02% 90
2020
Q4 		$13.4M Sell
857,339
-92,484
-10% -$1.08M 0.05% 66
2020
Q3 		$8.98M Sell
949,823
-50,000
-5% -$541K 0.04% 69
2020
Q2 		$8.96M Hold
999,823
– – 0.04% 65
2020
Q1 		$6.37M Hold
999,823
– – 0.04% 57
2019
Q4 		$8.37M Hold
999,823
– – 0.04% 57
2019
Q3 		$9.05M Hold
999,823
– – 0.06% 52
2019
Q2 		$10.8M Hold
999,823
– – 0.07% 51
2019
Q1 		$9.54M Hold
999,823
– – 0.06% 48
2018
Q4 		$11.5M Sell
999,823
-284,100
-22% -$3.53M 0.09% 46
2018
Q3 		$21.8M Hold
1,283,923
– – 0.14% 40
2018
Q2 		$18.2M Sell
1,283,923
-323,656
-20% -$5.38M 0.14% 43
2018
Q1 		$30.5M Sell
1,607,579
-505,797
-24% -$10.8M 0.26% 33
2017
Q4 		$34.7M Hold
2,113,376
– – 0.3% 32
2017
Q3 		$31.7M Sell
2,113,376
-2,000,000
-49% -$22.1M 0.26% 25
2017
Q2 		$36.2M Sell
4,113,376
-417,525
-9% -$2.68M 0.32% 22
2017
Q1 		$23.6M Buy
4,530,901
+475,025
+12% +$1.91M 0.19% 32
2016
Q4 		$12.4M Hold
4,055,876
– – 0.12% 45
2016
Q3 		$18.8M Hold
4,055,876
– – 0.17% 36
2016
Q2 		$23.5M Hold
4,055,876
– – 0.25% 30
2016
Q1 		$24.5M Hold
4,055,876
– – 0.26% 31
2015
Q4 		$37M Buy
4,055,876
+300,000
+8% +$2.31M 0.31% 30
2015
Q3 		$21.2M Buy
3,755,876
+524,944
+16% +$4.33M 0.2% 41
2015
Q2 		$35.8M Buy
3,230,932
+1,826,388
+130% +$23.5M 0.31% 33
2015
Q1 		$22M Buy
1,404,544
+449,212
+47% +$6.95M 0.18% 41
2014
Q4 		$14.5M Buy
955,332
+90,476
+10% +$1.1M 0.15% 43
2014
Q3 		$9.33M Buy
864,856
+342,092
+65% +$4.47M 0.12% 46
2014
Q2 		$7.98M Hold
522,764
– – 0.1% 49
2014
Q1 		$9.45M Buy
522,764
+98,456
+23% +$1.9M 0.12% 48
2013
Q4 		$5.89M Buy
424,308
+247,601
+140% +$2.85M 0.08% 60
2013
Q3 		$1.85M Buy
+176,707
New +$1.75M 0.03% 71

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Baker Bros. Advisors's SGMO Position: Q2 2021 in Review

Baker Bros. Advisors sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2021, closing a stake of 429,063 shares — an estimated $5.38M sold.

Baker Bros. Advisors first reported a position in SGMO in Q3 2013 and held it in 31 quarters. The position peaked at $37M in Q4 2015. 197 funds tracked by Wall St. Rank hold SGMO as of Q2 2021.

  • Baker Bros. Advisors reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2021 after selling out during the quarter.
  • Baker Bros. Advisors sold 429,063 SANGAMO THERAPEUTICS INC shares in Q2 2021, an estimated $5.38M.
  • Baker Bros. Advisors first reported a position in SANGAMO THERAPEUTICS INC in Q3 2013 and held it in 31 quarters.
  • Baker Bros. Advisors's SANGAMO THERAPEUTICS INC position peaked at $37M in Q4 2015.
  • 197 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2021.

Based on Baker Bros. Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.